Buscar
Soligenix Inc
SNGXAñadir a la lista de seguimiento
0.371USD
-0.004-0.99%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
3.91MCap. mercado
PérdidaP/E TTM
Más Datos de Soligenix Inc Compañía
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Información de Soligenix Inc
Símbolo de cotizaciónSNGX
Nombre de la empresaSoligenix Inc
Fecha de salida a bolsaApr 04, 1994
Director ejecutivoSchaber (Christopher J)
Número de empleados14
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 04
Dirección29 Emmons Drive
CiudadPRINCETON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08540
Teléfono16095388200
Sitio Webhttps://www.soligenix.com/
Símbolo de cotizaciónSNGX
Fecha de salida a bolsaApr 04, 1994
Director ejecutivoSchaber (Christopher J)
Ejecutivos de Soligenix Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Soligenix Inc?
Los cinco principales accionistas de Soligenix Inc son: Dr. Christopher J. (Chris) Schaber, Ph.D.
¿Cuántas instituciones poseen acciones de Soligenix Inc (SNGX)?
A fecha de 2026Q1, 46 instituciones poseen acciones de Soligenix Inc, con un valor de mercado combinado de aproximadamente 528.92K, lo que representa el 5.13% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1090679.00.